Dr. Raman Gangakhedkar, the former scientist of the Indian Council of Medical Research (ICMR), mentioned that a very small percentage of individuals might be at risk of experiencing side effects from the Covishield COVID-19 vaccine. Gangakhedkar highlighted this during an interview, addressing concerns regarding the vaccine’s rare side effects. According to him, only a minimal number of seven to eight people out of 10 lakh who receive the Covishield vaccine may face the risk of developing Thrombosis Thrombocytopenia Syndrome (TTS), as reported by Source.
Gangakhedkar emphasized that the risk is highest after the first dose, decreases with the second dose, and is lowest after the third dose. He also mentioned that any potential side effects are likely to manifest within the initial two to three months. Despite acknowledging the rare side effect, Gangakhedkar pointed out that the vaccine has had a positive impact on millions of recipients, making the associated risk minimal. The vaccine, developed by AstraZeneca in collaboration with the University of Oxford, was produced in India by the Serum Institute of India (SII), the largest vaccine manufacturer globally.
In a statement, an AstraZeneca spokesperson expressed their condolences to those who have experienced the loss of loved ones or health issues. They emphasized that patient safety is their top priority and regulatory authorities have strict standards in place to ensure the safe usage of all medicines, including vaccines.
Amidst the controversy, the Samajwadi Party claimed that the BJP received a “commission” from the COVID-19 vaccine manufacturer. Furthermore, the RJD accused the government of administering the “wrong” vaccine to the people of the country. Delhi Health Minister Saurabh Bharadwaj urged the Centre to promptly address the alleged side effects.